Takeda Continues to Advance Growth Strategy with Sale Of Non-Core Assets in Latin America

September 16, 2021
  • Takeda Continues to Focus its Portfolio on Growth in Key Therapeutic Areas Globally and Across Latin America
  • Through this Agreement, Takeda Will Divest a Selection of Non-core Products in Several Latin American Countries to Adium
  • Takeda Will Continue Developing and Delivering these Products to Adium, Granting Patients' Continuous Access Over the Next Five Years

BUENOS AIRES, Argentina, September 16, 2021 - Today, Takeda Pharmaceutical Company Limited  (TSE:4502/NYSE:TAK) ("Takeda") announced that it has entered into an agreement to divest a selection of non-core products from the Company's portfolio sold in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica, Panama and other countries in Central America and the Caribbean that make up the South Cone, Andean Region, Mexico and Central America and Caribbean regions (SAM) in its Growth and Emerging Markets Business Unit (GEM BU) to Adium Pharma S.A. ("Adium"), subject to customary legal and regulatory closing conditions.

The portfolio to be divested includes five non-core products mostly prescription gastroenterology assets:
Pantoprazole, Alevian, Dexlansoprazole, Riopan, Faktu. The transaction is expected to close in the second half of 2021, subject to the satisfaction of customary closing conditions. Until then, Takeda remains the owner of these products and is responsible for ensuring patient access to them.

"We are confident that Adium is well-positioned to guarantee patients' continuous access to the products subject to this transaction," said Ricardo Marek, president of Takeda's Growth & Emerging Markets (GEM) Business Unit (BU). "The strategy adopted by our GEM BU contributes to accelerate patients' sustainable access to innovation. Through this divestment, we will have a greater ability to focus on strengthening our efforts in key therapeutic to meet the needs of patients living with a serious or rare disease. Furthermore, it helps Takeda achieve our ambition to become a global, value-based, R&D-driven biopharmaceutical leader."

Adium, a pharmaceutical company founded in 1975 headquartered in Uruguay, operates in 18 Latin American countries, dedicated to the development, production and commercialization of pharmaceutical products, providing access to doctors and patients in Latin America, to innovative and quality treatments with a commercial portfolio that includes proprietary branded generics and innovative pharmaceutical licensed products in the areas of oncology, rheumatology, pain, urology, women's health, neurology, cardiology and gastroenterology.

"The divestment reinforces Takeda's commitment to deliver highly innovative products by sharpening our focus on our five strategic business areas as part of our global strategy for long-term growth", stated Gabriela Pittis, president of the SAM area for Takeda's GEM BU. "Pursuant to this agreement, Takeda will keep on developing and supplying the products object to this contract for the next five years to Adium, in line with the Company's purpose to provide better health for people and a brighter future for the world.".

Takeda has entered into an agreement to divest its portfolio of five pharmaceutical products, mostly prescription assets sold in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica and Panama, as well as in other countries in Central America and the Caribbean to Adium, subject to customary legal and regulatory closing conditions.

Under this agreement, Takeda remains responsible for developing and delivering these products to Adium over the next five years, which will enable patients to have continuous access to these medicines. 

Takeda is being advised by Deloitte as our financial advisor and Marval O'Farrell & Mairal as our legal advisor in this transaction.

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Takeda GEM BU
Florencia Sierra
florencia.sierra@takeda.com
+54 9 11 5586 6768

JM Oribe Comunicaciones
José María Oribe
jmoribe@jmoribe.com
+ 54 9 11 5412-0205

Contact for Investors:
Takashi Okubo
+81-(0)3-3278-2306
takeda.ir.contact@takeda.com 

For the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

To read more Press Release articles, click here.